Literature DB >> 20352171

Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review.

Ida Martinelli1, Valerio De Stefano.   

Abstract

Venous thrombosis typically involves the lower extremity circulation. Rarely, it can occur in the cerebral or splanchnic veins and these are the most frightening manifestations because of their high mortality rate. A third site of rare venous thrombosis is the deep system of the upper extremities that, as for the lower extremity, can be complicated by pulmonary embolism and post-thrombotic syndrome. The authors conducted a narrative review focused on clinical manifestations, risk factors, and treatment of rare venous thromboses. Local risk factors such as infections or cancer are frequent in thrombosis of cerebral or portal veins. Upper extremity deep-vein thrombosis is mostly due to local risk factors (catheter- or effort-related). Common systemic risk factors for rare venous thromboses are inherited thrombophilia and oral contraceptive use; chronic myeloproliferative neoplasms are closely associated with splanchnic vein thrombosis. In the acute phase rare venous thromboses should be treated conventionally with low-molecular-weight heparin. Use of local or systemic fibrinolysis should be considered in the case of clinical deterioration in spite of adequate anticoagulation. Anticoagulation with vitamin K-antagonists is recommended for 3-6 months after a first episode of rare venous thrombosis. Indefinite anticoagulation is recommended for Budd-Chiari syndrome, recurrent thrombosis or unprovoked thrombosis and permanent risk factors. In conclusion, the progresses made in the last couple of decades in diagnostic imaging and the broadened knowledge of thrombophilic abnormalities improved the recognition of rare venous thromboses and the understanding of pathogenic mechanisms. However, the recommendations for treatment mainly derive from observational studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20352171     DOI: 10.1160/TH09-12-0873

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  Pathophysiology of thrombosis in myeloproliferative neoplasms.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

Review 2.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

3.  Polycythemia vera: gender-related phenotypic differences.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro; Maria Anna Nicolazzi; Igor Giarretta; RosaMaria Marfisi; Roberto Marchioli
Journal:  Intern Emerg Med       Date:  2011-06-10       Impact factor: 3.397

Review 4.  Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.

Authors:  David J Araten; Rosario Notaro; Howard T Thaler; Nancy Kernan; Farid Boulad; Hugo Castro-Malaspina; Trudy Small; Andromachi Scaradavou; Heather Magnan; Susan Prockop; Sara Chaffee; Jason Gonsky; Raymond Thertulien; Roberto Tarquini; Lucio Luzzatto
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

Review 5.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 6.  Venous Thromboembolism and Cancer.

Authors:  Alec A Schmaier; Paurush Ambesh; Umberto Campia
Journal:  Curr Cardiol Rep       Date:  2018-08-20       Impact factor: 2.931

Review 7.  Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis.

Authors:  Laura M Attard; Alex Gatt; Laurent Bertoletti; Aurelien Delluc; Nicoletta Riva
Journal:  Vasc Health Risk Manag       Date:  2022-10-13

8.  Prevention and treatment of cancer-associated thrombosis.

Authors:  S Ng; M Carrier
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

Review 9.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

10.  Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study.

Authors:  Nicoletta Riva; Walter Ageno; Daniela Poli; Sophie Testa; Serena Rupoli; Rita Santoro; Teresa Lerede; Antonietta Piana; Monica Carpenedo; Alberto Nicolini; Piera Maria Ferrini; Giuliana Martini; Catello Mangione; Laura Contino; Carlo Bonfanti; Paolo Gresele; Alberto Tosetto
Journal:  Gastroenterol Res Pract       Date:  2015-10-05       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.